ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

MESNEX INJECTION
Cytoprotective and supportive care agents
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

MESNEX INJECTION Rx

Generic Name and Formulations:
Mesna 100mg/mL; soln for IV inj after dilution; contains benzyl alcohol.

Company:
Baxter

Therapeutic Use:

Indications for MESNEX INJECTION:

Prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.

Limitations Of use:

Not indicated to reduce the risk of hematuria due to other conditions (eg, thrombocytopenia).

Adult:

See full labeling. IV schedule: give as IV bolus inj in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration and 4 and 8hrs after each dose of ifosfamide; total daily dose is 60% the ifosfamide dose. IV and oral schedule: give as IV bolus inj in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration, followed by the tablets given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6hrs after each dose of ifosfamide; total daily dose is 100% of the ifosfamide dose. Repeat schedule on each day ifosfamide is given. If vomiting occurs within 2hrs of oral mesna, repeat dose or give IV mesna.

Children:

Not established.

Warnings/Precautions:

Monitor urine for the presence of hematuria each day prior to ifosfamide therapy; consider dose reduction or discontinue ifosfamide if severe hematuria occurs. Hypersensitivity to thiol compounds. Discontinue and treat if hypersensitivity or serious skin reactions (eg, SJS, TEN) occur. Maintain adequate hydration. Inj: avoid in premature neonates and low-birth weight infants. Elderly. Pregnancy: exclude status prior to initiation. Use effective contraception during and for 6 months (females) or 3 months (males w. female partners) after the last dose. Nursing mothers: not recommended (during and for 1 week after the last dose).

See Also:

MESNEX

Pharmacological Class:

Cytoprotective agent.

Interactions:

May cause false (+) ketones in nitroprusside sodium-based urine tests and ascorbic acid in Tillman's urine tests. May interfere with enzymatic CPK activity tests.

Adverse Reactions:

With ifosfamide: nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, somnolence.

Note:

Patients taking mesna should drink at least a quart of liquid a day.

How Supplied:

Tabs—10; Multidose vials—1, 10

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs